Loading...
XNASSPRC
Market cap2mUSD
Dec 23, Last price  
0.23USD
1D
9.14%
1Q
-8.31%
IPO
-99.87%
Name

Scisparc Ltd

Chart & Performance

D1W1MN
XNAS:SPRC chart
P/E
—
P/S
0.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-44.81%
Rev. gr., 5y
28.00%
Revenues
3m
+113.73%
00000487,000838,000498,000550,0001,069,0001,347,0002,879,000
Net income
-5m
L+97.61%
059,440000-6,244,000-8,523,000-5,362,000-3,507,000-5,801,000-2,592,000-5,122,000
CFO
-6m
L-25.64%
00000-4,579,000-7,132,000-4,696,000-4,307,000-5,061,000-7,917,000-5,887,000

Profile

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
URL
https://scisparc.com/
IPO date
Dec 22, 2021
Employees
3
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,879
113.73%
1,347
26.01%
1,069
94.36%
Cost of revenue
8,652
8,664
5,671
Unusual Expense (Income)
NOPBT
(5,773)
(7,317)
(4,602)
NOPBT Margin
Operating Taxes
22
14
12
Tax Rate
NOPAT
(5,795)
(7,331)
(4,614)
Net income
(5,122)
97.61%
(2,592)
-55.32%
(5,801)
65.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,552
9,005
7,699
BB yield
-278.85%
-260.53%
-60.31%
Debt
Debt current
52
27
486
Long-term debt
100
27
81
Deferred revenue
Other long-term liabilities
1,226
Net debt
(6,364)
(4,841)
(6,308)
Cash flow
Cash from operating activities
(5,887)
(7,917)
(5,061)
CAPEX
(4,869)
(35)
Cash from investing activities
(1,109)
(7,084)
(70)
Cash from financing activities
5,498
11,700
10,060
FCF
(5,846)
(5,618)
(6,373)
Balance
Cash
5,076
3,574
6,875
Long term investments
1,440
1,321
Excess cash
6,372
4,828
6,822
Stockholders' equity
9,587
(4,480)
(1,939)
Invested Capital
3,291
10,956
10,584
ROIC
ROCE
EV
Common stock shares outstanding
408
176
79
Price
4.88
-75.16%
19.64
-87.87%
161.98
 
Market cap
1,991
-42.40%
3,456
-72.92%
12,765
 
EV
(2,400)
(1,385)
6,457
EBITDA
(5,235)
(7,130)
(4,569)
EV/EBITDA
0.46
0.19
Interest
36
12
Interest/NOPBT